

## RYALTRIS - (0.025MG/SPRAY;0.665MG/SPRAY ; SPRAY,METERED)

<b>Generic Name</b>	MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE	<b>Innovator</b>	Glenmark
<b>Dosage</b>	0.025MG/SPRAY;0.665MG/SPRAY ; SPRAY,METERED	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	Less Than 5	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	RYALTRIS is a combination of olopatadine, a histamine-1 (H1)receptor inhibitor, and mometasone furoate, a corticosteroid, indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.